Advances in Chronic Kidney Disease
Volume 15, Issue 3 , Pages 213-221 , July 2008

Acute Kidney Injury: Definitions and New Paradigms

  • Zoltán H. Endre

      Affiliations

    • Corresponding Author InformationAddress correspondence to Zoltán H. Endre, MD, Department of Medicine, University of Otago–Christchurch, PO Box 4345, Christchurch, New Zealand.

References 

  1. Liano F, Pascual J. Epidemiology of acute renal failure: A prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. Kidney Int. 1996;50:811–818
  2. Lameire N, Hoste E. Reflections on the definition, classification, and diagnostic evaluation of acute renal failure. Curr Opin Crit Care. 2004;10:468–475
  3. Mehta RL, Pascual MT, Soroko S, et al. Spectrum of acute renal failure in the intensive care unit: The PICARD experience. Kidney Int. 2004;66:1613–1621
  4. Hoste EA, Clermont G, Kersten A, et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: A cohort analysis. Crit Care. 2006;10:R73
  5. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005;365:417–430
  6. Brivet FG, Kleinknecht DJ, Loirat P, et al. Acute renal failure in intensive care units—Causes, outcome, and prognostic factors of hospital mortality; A prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med. 1996;24:192–198
  7. Vincent JL. Incidence of acute renal failure in the intensive care unit. Contrib Nephrol. 2001;132:1–6
  8. Mehta R, Kellum J, Shah S, et al. Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:R31
  9. Van Biesen W, Vanholder R, Lameire N. Defining acute renal failure: RIFLE and beyond. Clin J Am Soc Nephrol. 2006;1:1314–1319
  10. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16:3365–3370
  11. Lassnigg A, Schmidlin D, Mouhieddine M, et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: A prospective cohort study. J Am Soc Nephrol. 2004;15:1597–1605
  12. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95:13–19
  13. Uchino S, Bellomo R, Goldsmith D, et al. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med. 2006;34:1913–1917
  14. McCullough PA, Soman SS. Contrast-induced nephropathy. Crit Care Clin. 2005;21:261–280
  15. Levy MM, Macias WL, Vincent JL, et al. Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med. 2005;33:2194–2201
  16. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure—Definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204–R212
  17. Westhuyzen J, Endre ZH, Reece G, et al. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant. 2003;18:543–551
  18. Zhou H, Hewitt SM, Yuen PST, et al. Acute kidney injury biomarkers—Needs, present status and future promise. Nephrology Self-Assessment Program. 2006;5:63–71
  19. Bjornsson TD. Use of serum creatinine concentrations to determine renal function. Clin Pharmacokinet. 1979;4:200–222
  20. Honore PM, Joannes-Boyau O, Boer W. The early biomarker of acute kidney injury: In search of the Holy Grail. Intensive Care Med. 2007;33:1866–1868
  21. Shemesh O, Golbetz H, Kriss JP, et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28:830–838
  22. Han WK, Bonventre JV. Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care. 2004;10:476–482
  23. Grenier N, Basseau F, Ries M, et al. Functional MRI of the kidney. Abdom Imaging. 2003;28:164–175
  24. Grenier N, Hauger O, Delmas Y, et al. MR imaging of nephropathies. Abdom Imaging. 2006;31:213–223
  25. Grenier N, Pedersen M, Hauger O. Contrast agents for functional and cellular MRI of the kidney. Eur J Radiol. 2006;60:341–352
  26. Endre ZH. Nephrogenic systemic fibrosis: Is any contrast safe in renal failure?. Intern Med J. 2007;37:429–431
  27. Endre ZH, Westhuyzen J. Early detection of acute kidney injury: Emerging new biomarkers. Nephrology (Carlton). 2008;73:1008–1016
  28. Coca SG, Yalavarthy R, Concato J, et al. Biomarkers for the diagnosis and risk stratification of acute kidney injury: A systematic review. Kidney Int. 2008;73:1008–1016
  29. Liangos O, Perianayagam MC, Vaidya VS, et al. Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007;18:904–912
  30. Edelstein CL. Biomarkers of Acute kidney injury. Adv Chronic Kidney Dis. 2008;15:222–234
  31. Supavekin S, Zhang W, Kucherlapati R, et al. Differential gene expression following early renal ischemia/reperfusion. Kidney Int. 2003;63:1714–1724
  32. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14:2534–2543
  33. Devarajan P, Mishra J, Supavekin S, et al. Gene expression in early ischemic renal injury: Clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol Genet Metab. 2003;80:365–376
  34. Mishra J, Mori K, Ma Q, et al. Neutrophil gelatinase-associated lipocalin: A novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol. 2004;24:307–315
  35. Mori K, Lee HT, Rapoport D, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005;115:610–621
  36. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231–1238
  37. Parikh CR, Jani A, Mishra J, et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant. 2006;6:1639–1645
  38. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol. 2006;26:287–292
  39. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, et al. Neutrophil gelatinase-associated lipocalin (NGAL) correlations with cystatin C, serum creatinine and eGFR in patients with normal serum creatinine undergoing coronary angiography. Nephrol Dial Transplant. 2007;22:295–296
  40. Trachtman H, Christen E, Cnaan A, et al. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: A novel marker of renal injury. Pediatr Nephrol. 2006;21:989–994
  41. Xu S, Venge P. Lipocalins as biochemical markers of disease. Biochim Biophys Acta. 2000;1482:298–307
  42. Han WK, Bailly V, Abichandani R, et al. Kidney injury molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62:237–244
  43. Ichimura T, Hung CC, Yang SA, et al. Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol. 2004;286:F552–F563
  44. Vella JP, Harris S, Garrison K, et al. Transcripts For kidney injury molecule-1 (Kim-1) are a specific biomarker predicting delayed graft function in kidney. Am J Transplant. 2006;6(suppl 2):201
  45. Parikh CR, Jani A, Melnikov VY, et al. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis. 2004;43:405–414
  46. Parikh CR, Abraham E, Ancukiewicz M, et al. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol. 2005;16:3046–3052
  47. Parikh CR, Mishra J, Thiessen-Philbrook H, et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int. 2006;70:199–203
  48. Herget-Rosenthal S, Pietruck F, Volbracht L, et al. Serum cystatin C—A superior marker of rapidly reduced glomerular filtration after uninephrectomy in kidney donors compared to creatinine. Clin Nephrol. 2005;64:41–46
  49. Herget-Rosenthal S, Marggraf G, Husing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004;66:1115–1122
  50. Westhuyzen J. Cystatin C: A promising marker and predictor of impaired renal function. Ann Clin Lab Sci. 2006;36:387–394
  51. Herget-Rosenthal S, Poppen D, Husing J, et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem. 2004;50:552–558
  52. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354:379–386
  53. Jo SK, Rosner MH, Okusa MD. Pharmacologic treatment of acute kidney injury: Why drugs haven't worked and what is on the horizon. Clin J Am Soc Nephrol. 2007;2:356–365
  54. Lewis J, Salem MM, Chertow GM, et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis. 2000;36:767–774
  55. Hirschberg R, Kopple J, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int. 1999;55:2423–2432
  56. Bagnis C, Beaufils H, Jacquiaud C, et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant. 2001;16:932–938
  57. Vesey DA, Cheung C, Pat B, et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004;19:348–355
  58. Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J. 2003;17:1754–1755
  59. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol. 1994;266:F360–F366
  60. Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004;15:2115–2124
  61. Patel NS, Sharples EJ, Cuzzocrea S, et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 2004;66:983–989
  62. Spandou E, Tsouchnikas I, Karkavelas G, et al. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant. 2006;21:330–336
  63. Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 2006;69:1806–1813

 Supported by Health Research Council Project grant 05/131.

PII: S1548-5595(08)00049-9

doi: 10.1053/j.ackd.2008.04.002

Advances in Chronic Kidney Disease
Volume 15, Issue 3 , Pages 213-221 , July 2008

Article Tools

* Image Usage & Resolution